* For research use only, not for use in diagnostic procedures.
The CDIATM Buprenorphine Colloidal Gold Test Cassette (Urine) is a lateral flow chromatographic immunoassay for the detection of buprenorphine and its metabolites in human urine.
Buprenorphine antigen is coated on the test region of the nitrocellulose membrane of the strips, and barbiturates antibody is labeled with colloid gold. During a test, the colloid gold labeled antibody coated in the strip move forward along the membrane, and a red line will show up when the antibody gathers with the antigen in the test line; if barbiturates in the sample is over the detection limit, line T is blank; on the other wise, if barbiturates in the sample is less than the detection limit, line T is red.
Buprenorphine is a potent analgesic often used in the treatment of opioid addiction. Therapeutically, Buprenorphine is used as a substitution treatment for opioid addicts. Substitution treatment is a form of medical care offered to opiate addicts (primarily heroin addicts) based on a similar or identical substance to the drug normally used. In substitution therapy, Buprenorphine is as effective as Methadone but demonstrates a lower level of physical dependence. Concentrations of free Buprenorphine and Norbuprenorphine in urine may be less than 1 ng/ml after therapeutic administration, but can range up to 20 ng/ml in abuse situations. The plasma half life of Buprenorphine is 2-4 hours. While complete elimination of a single dose of the drug can take as long as 6 days, the window of detection for the parent drug in urine is thought to be approximately 3 days.The CDIATM Buprenorphine Colloidal Gold Test Cassette (Urine) is a rapid urine-screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of buprenorphine in urine. The CDIATM Buprenorphine Colloidal Gold Test Cassette (Urine) yields a positive result when the buprenorphine in urine exceeds 10 ng/mL.